Revenue
2018
2019
2020
2021
2022
2023
2024
2025
Nanobiotix (NANO)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | €29.6M | −€11.6M | €30.1M | €4.8M | €2.6M | €2.5M | €2.5M | €3.5M |
| Research & development | €23.1M | €40.5M | €38.4M | €32.6M | €30.4M | €24.3M | €30.4M | €20.9M |
| Operating expenses | €43.4M | €61.2M | €63.0M | €51.5M | €55.2M | €38.9M | €49.3M | €33.5M |
| Operating income | −€10.8M | −€68.4M | −€26.8M | −€46.7M | −€52.6M | −€36.4M | −€46.8M | −€30.1M |
| Operating margin | −36.49% | — | −89.09% | −977.85% | −1,986.36% | −1,450.16% | −1,840.97% | −864.24% |
| EBITDA | −€9.3M | −€66.8M | −€25.3M | −€45.2M | −€51.0M | −€34.7M | −€45.0M | −€29.4M |
| EBITDA margin | −31.45% | — | −84.06% | −946.44% | −1,927.43% | −1,380.33% | −1,771.43% | −846.45% |
| Net income | −€24.0M | −€68.1M | −€39.7M | −€57.0M | −€47.0M | −€33.6M | −€50.9M | −€30.3M |
| Net profit margin | −80.83% | — | −132.08% | −1,194.33% | −1,775.71% | −1,337.18% | −2,003.74% | −872.23% |
| Basic EPSper basic share | -€0.50 | -€1.44 | -€1.08 | -€1.64 | -€1.35 | -€1.38 | -€0.00 | -€0.00 |
| Diluted EPSper diluted share | -€0.50 | -€1.44 | -€1.08 | -€1.64 | -€1.35 | -€1.38 | -€0.00 | -€0.00 |